RapidAI has been named to CB Insights’ fifth-annual Digital Health 50 (formerly Digital Health 150), a list of the 50 most promising private digital health companies of 2023.
The company recently launched its Edge Cloud Platform and received both Shonin (premarket approval) clearance and 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Rapid SDH detection tool for CT imaging. This came after RapidAI completed a $75 million series C funding round earlier in 2023.
The 2023 Digital Health 50 honorees were selected from a pool of over 10,000 companies. RapidAI was selected within the "Diagnosis & Imaging" category, which honors companies focused on early detection and diagnosis.
